NCT01660152

Brief Summary

The purpose of this study is to determine which technique in using a vacuum erection device (VED) is best. Erectile dysfunction (ED) after robotic prostate cancer surgery is a concern for both the surgeon and the patient. Recent studies have shown that beginning to use the vacuum pump on a daily basis starting with in 2-8 weeks may help prevent the start of penile shrinkage. This is a potential issue that can occur because of decreased blood flow after prostate cancer surgery. This study will allow researchers to determine and compare vacuum therapy techniques and erectile function outcomes of patients who have prostate cancer surgery

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

August 6, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 8, 2012

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 17, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 17, 2013

Completed
Last Updated

April 13, 2017

Status Verified

April 1, 2017

Enrollment Period

1.9 years

First QC Date

August 6, 2012

Last Update Submit

April 12, 2017

Conditions

Keywords

male erectile disorderprostate cancerLaparoscopic prostatectomy

Outcome Measures

Primary Outcomes (3)

  • Changes in sexual function based on the self reported SHIM assessment and penile morphometric outcomes based on penile dimension measurements at rest

    Summarized according to assigned treatment group. Linear mixed models will be used to model the changes over time.

    3 months post-surgery

  • Changes in sexual function based on the self reported SHIM assessment and penile morphometric outcomes based on penile dimension measurements at rest

    Summarized according to assigned treatment group. Linear mixed models will be used to model the changes over time.

    6 months post-surgery

  • Changes in sexual function based on the self reported SHIM assessment and penile morphometric outcomes based on penile dimension measurements at rest

    Summarized according to assigned treatment group. Linear mixed models will be used to model the changes over time.

    12 months post-surgery

Secondary Outcomes (1)

  • Compliance and overall patient satisfaction (1 to 25 point scale) based on the self reported compliance diary and SHIM questionnaires

    Up to 12 months post-surgery

Study Arms (2)

Group A (vacuum therapy, holding erection for 2 minutes)

EXPERIMENTAL

Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.

Other: Sexual Health Inventory for Men (SHIM) questionnaire administrationProcedure: management of therapy complicationsProcedure: Daily vacuum therapy

Group B (vacuum therapy, holding erection for 5 minutes)

EXPERIMENTAL

Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.

Other: Sexual Health Inventory for Men (SHIM) questionnaire administrationProcedure: management of therapy complicationsProcedure: Daily vacuum therapy

Interventions

Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.

Also known as: assessment
Group A (vacuum therapy, holding erection for 2 minutes)Group B (vacuum therapy, holding erection for 5 minutes)

Receive VED

Also known as: complications of therapy, management of
Group A (vacuum therapy, holding erection for 2 minutes)Group B (vacuum therapy, holding erection for 5 minutes)

Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.

Group A (vacuum therapy, holding erection for 2 minutes)Group B (vacuum therapy, holding erection for 5 minutes)

Eligibility Criteria

AgeUp to 70 Years
Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Sexually active men without the consistent use of erectile aids pre-operatively (i.e. oral pharmacotherapy, intraurethral prostoglandin E1 \[PGE1\], intracavernosal injection therapy and penile implants)
  • Undergoing a bilateral nerve sparing robotic prostatectomy
  • Pre-operative baseline SHIM total score of greater than or equal to 17
  • Presence of a female sexual partner
  • Dexterity necessary to operate vacuum pump

You may not qualify if:

  • Has a history of cardiac failure, angina, or life-threatening arrhythmia within the past 6 months
  • Has taken or has been prescribed nitrate medication in any form in the last 6 months
  • Has a known sensitivity to Phosphodiesterase type 5 inhibitors such as Sildenafil, Tadalafil or Vardenafil
  • Men with sickle cell anemia
  • Men with insufficient manual dexterity to operate vacuum device
  • Men with a history of known penile deformity or Peyronie's disease
  • Pre or postoperative androgen therapy
  • Pre or postoperative radiation therapy to pelvic area
  • Men actively smoking at time of enrollment, 1 pack per day or more

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ohio State University Medical Center

Columbus, Ohio, 43210, United States

Location

Related Links

MeSH Terms

Conditions

Erectile DysfunctionProstatic NeoplasmsSexual Dysfunction, Physiological

Interventions

Menogarilmethyl 3-mercaptopropionimidateRestraint, Physical

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental DisordersGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsProstatic Diseases

Intervention Hierarchy (Ancestors)

NogalamycinDaunorubicinAnthracyclinesNaphthacenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic CompoundsAminoglycosidesGlycosidesCarbohydratesBehavior ControlTherapeuticsImmobilizationInvestigative Techniques

Study Officials

  • Ronney Abaza, MD

    Ohio State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2012

First Posted

August 8, 2012

Study Start

September 1, 2011

Primary Completion

July 17, 2013

Study Completion

July 17, 2013

Last Updated

April 13, 2017

Record last verified: 2017-04

Locations